Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Life Cycle Assessment | LCA conducted for products | Achieved |
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary: Aarti Pharmalabs Limited** Aarti Pharmalabs faces its highest financial exposure through compliance risk (10.0/10 score), with estimated remediation costs of ₹3–11 crore driven by gaps in SEBI BRSR Core Expansion disclosures and potential environmental non-compliance across water and GHG intensity metrics. As a pharmaceutical API manufacturer, the company is subject to mandatory BRSR P6 environmental reporting and risks SEBI enforcement action or delisting if disclosure gaps persist, particularly given its ₹1,786 crore revenue scale. Water intensity emerges as a critical operational concern for API production, though absence of reported Scope 1/2 emissions suggests incomplete measurement systems rather than genuine low exposure—at India's CCTS carbon price of ₹600–900/tonne, unmeasured emissions create hidden liabilities. Immediate priority: establish robust GHG and water accounting protocols and close BRSR disclosure gaps within one financial year to mitigate regulatory penalties and investor credibility loss.
Source: Aarti Pharmalabs Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.